This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Rare Disease Conference 2024 - Rare Disease Summit
March 19-21, 2024
Pre-Conference Workshops on March 18, 2024Philadelphia Marriott Downtown | Philadelphia, PA

Melissa Leichter
Vice President, Commercial Lead, Rare Disease at Novo Nordisk


Melissa Leichter is a senior commercial executive with 25+ years of experience developing and leading highly efficient, people-centric organizations in the healthcare industry. Her career is deeply rooted in biotechnology—with expertise in rare diseases—combined with a background with mid- to large-sized pharmaceutical companies.

As VP/Commercial Lead, Rare Disease for Novo Nordisk Inc. (NNI), Melissa brought together teams from across the enterprise to achieve an ambitious goal—to exceed $1B in annual revenue. By merging big-picture vision with hands-on commercial leadership, she reached the objective in less than 12 months. In earlier roles with NNI, she led product launches, staved off competitors, and brought new energy to mature brands.

Before joining NNI, Melissa fueled growth across therapeutic areas for Johnson & Johnson (now Janssen), where she earned many awards while progressing through a series of positions in sales, training, product management, and brand innovation. Melissa holds a BA in Business and Economics from the University of Pittsburgh.

Agenda Sessions

  • Helpful or Harmful – Using AI in the Rare Disease Space